Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection

Ascione, Antonio; Luca, Massimo De; Tartaglione, M.T.; Lampasi, F.; Costanzo, Giovan Giuseppe Di; Lanza, A; Picciotto, Francesco; Marino-Marsilia, G.; Fontanella, Luca; Leandro, Gioacchino

doi:10.1053/j.gastro.2009.10.005

Cited by 156 publications

(144 citation statements)

References 12 publications

Supporting

Mentioning

126

Contrasting

Order By: Relevance

“…By contrast, Ascione et al reported a significant difference in relapse rates: 20.4% with peginterferon alfa-2a and 9.7% with peginterferon alfa-2b (95% CI, 0.38-21.2; p = 0.040) [5]. In the IDEAL study, McHutchison et al reported relapse rates of 31.5% for peginterferon alfa-2a and 23.5% for alfa-2b, although these did not differ significantly [8].…”

Section: Discussionmentioning

confidence: 72%

“…However, some authors have reported better responses with peginterferon alfa-2a. In 2010, Ascione et al reported a prospective single-center, open-label randomized trial (n = 320), which showed that 54.8% of patients treated with peginterferon alfa-2a had an SVR compared with 39.8% of patients treated with peginterferon alfa-2b (95% CI, 0.72-28.5; p = 0.040) [5]. Similar results were reported by Rumi et al in a single-center, open-label randomized trial, which found response rates of 48% in patients who received peginterferon alfa-2a (n = 212) and 32% in patients who received peginterferon alfa-2b (n = 219) (p = 0.04) [13].…”

Section: Discussionmentioning

confidence: 99%

“…A few studies have compared the effectiveness and safety of peginterferon alfa-2a and alfa-2b, but all have used different statistical designs and the results are inconclusive [2,5,6,8]. However, clinical trials provide a high level of medical and supportive care, which tends to maximize patient compliance, and the inclusion and exclusion criteria may not reflect the clinical picture in a real-life setting [11].…”

Section: Introductionmentioning

confidence: 99%

“…The primary goal of HCV therapy is to cure the infection by eliminating detectable circulating HCV after the cessation of treatment [4]. Two types of peginterferon are available -peginterferon alfa-2a and peginterferon alfa-2b -and both are recommended for the treatment of HCV, although there is controversy over which treatment option is the most effective [5,6]. Well-known factors that affect the response to treatment include baseline characteristics such as the HCV genotype, HCV RNA viral load, age, and the degree of fibrosis [7].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C

Sandoval-Ramírez

Mata‐Marín

García

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in lowincome countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective. Methodology: This was a retrospective cohort study at a infectious disease center in Mexico City. Patients were included if they had received peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. Age, sex, body mass index, AST platelet ratio index, HCV RNA viral load, levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts of the subjects were assessed before treatment and at weeks 4, 12, 24, 48, and 6 months post treatment. Results: Eighty-seven patients met the inclusion criteria. A sustained virological response (SVR) occurred in 33 (38%) of them, 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). Seventeen patients (20%) relapsed, 7 (41%) of those given peginterferon alfa-2a and 10 (59%) of those given peginterferon alfa-2b (p = 0.76); 27 (31%) patients were non-responders (p = 0.09). The rates of anemia, thrombocytopenia, and leukopenia were similar in both groups. Conclusions: Similar SVR rates and frequencies of adverse events were observed. Either type of interferon can be used to treat HCV infection in the Mexican population

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C

Sandoval-Ramírez

Mata‐Marín

García

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…In a study carried out in Italy, it was reported that SVR rates obtained with PEG-IFN α-2A and RIB combination were significantly higher than the SVR rates obtained with PEG-IFN α-2B and RIB combination both in genotype 1-4 and genotype 2-3 patients; however, the adverse effects observed in patients in both branches of treatment were similar (13).…”

Section: Discussionmentioning

confidence: 90%